logo-loader
viewReNeuron Group PLC

Jefferies 2019 Global Healthcare Conference

/**/ h1{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}h3{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}link{ color: #0563C1 }visited{ color: #954F72 } .x{size:612.0pt 792.0pt;margin:63.8pt 72.0pt 72.0pt 72.0pt;}div.x{}span.bg{font-weight:normal}table.bi{margin-left:-5.4pt;border-collapse:collapse}tr.bb{height:18.1pt}td.be{width:199.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:18.1pt}span.bf{font-family:"Calibri","sans-serif"}td.bc{width:238.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:18.1pt}h3.bd{text-align: right}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";} span.az{font-size:12.0pt;line-height:107%}p.bj{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.bk{color: black; font-family: "Calibri","sans-serif"; font-weight: bold}span.bl{font-family:"Calibri","sans-serif"; color:black}p.bm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center; text-autospace: none}span.av{font-size:12.0pt}p.bn{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-autospace: none}span.at{font-size:12.0pt; font-family:TrebuchetMS-Bold}p.bo{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;text-autospace:none}span.r{} span.bp{font-size:12.0pt}p.bq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}p.br{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;font-weight: bold; text-align: center}table.bs{margin-left:-10.8pt;border-collapse:collapse;border:none}tr.al{height:28.75pt}td.an{width:299.4pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:28.75pt}p.bt{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;font-weight: bold}td.am{width:138.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:28.75pt}p.s,li.s,div.s{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;}tr.aj{height:6.0pt} td.ak{width:448.2pt;border:none; padding:0cm 5.4pt 0cm 5.4pt;height:6.0pt}td.ai{width:299.4pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}td.ah{width:138.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}tr.ae{height:20.6pt}td.ag{width:299.4pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:20.6pt}td.af{width:138.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:20.6pt}tr.ab{height:12.65pt}td.ad{width:299.4pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:12.65pt}td.ac{width:138.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:12.65pt}p.bu{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;text-align:justify} span.bv{font-size:9.5pt;font-family:"Trebuchet MS","sans-serif"; color:black;border:none} /**/
RNS Number : 7207A
ReNeuron Group plc
31 May 2019
 

 

 

31 May 2019

 

AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Jefferies 2019 Global Healthcare Conference

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that the Company's management team will be participating in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday 4 June 2019 in New York City.

 

For further information on the conference, please visit the following link: Jefferies 2019 Global Healthcare Conference 

 

ENDS

 

Contacts:

 

ReNeuron

 

 

+44 (0) 20 3819 8400

Olav Hellebø, Chief Executive Officer

Michael Hunt, Chief Financial Officer

 

Buchanan (UK Media/Investor Relations)

 

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham

 

Argot Partners (US Media/Investor Relations)

Claudia Styslinger, David Rosen

 

+1 212 600 1902 or email

[email protected]

 

 

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Jonathan Senior, Stewart Wallace, Ben Maddison

+44 (0) 20 7710 7600

 

 

N+1 Singer (Joint Broker)

Aubrey Powell, Mark Taylor

 

+44 (0) 20 7496 3000

 

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off-the-shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRACKDDPPBKKNPN

Quick facts: ReNeuron Group PLC

Price: 132.5

Market: LSE
Market Cap: £42.18 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Punchy read-through valuation for ADM Energy's Nigerian oil...

Headlines from the Proactive UK newsroom. ADM Energy (LON:ADME) has had a punchy read-through valuation placed on its 5% stake in its field, offshore Nigeria. Petronor has acquired a 12.2% economic interest for US$10mln with a further US$25mln based on future gas production. Reneuron...

on 23/10/19